1![Day by Day Program Sunday 25th March 2:00- 6:00pm Conference Registration Desk Opens (Wandiny Room) Day by Day Program Sunday 25th March 2:00- 6:00pm Conference Registration Desk Opens (Wandiny Room)](https://www.pdfsearch.io/img/5ee24714bab49ec5bcdbd01409c76650.jpg) | Add to Reading ListSource URL: www.sapro.com.auLanguage: English - Date: 2012-03-15 17:19:40
|
---|
2![FLT3 Ligand Fms-like Tyrosine Kinase 3 Ligand human, recombinant, E. coli Cat. No. FLT3 Ligand Fms-like Tyrosine Kinase 3 Ligand human, recombinant, E. coli Cat. No.](https://www.pdfsearch.io/img/cf642c15903dd255ce1e589eed382d05.jpg) | Add to Reading ListSource URL: www.jenabioscience.comLanguage: English - Date: 2014-04-14 06:01:17
|
---|
3![AMBIT BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP TO RESEARCH, DEVELOP AND COMMERCIALIZE FLT3 KINASE INHIBITORS IN MULTIPLE INDICATIONS Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million AMBIT BIOSCIENCES AND ASTELLAS ENTER STRATEGIC PARTNERSHIP TO RESEARCH, DEVELOP AND COMMERCIALIZE FLT3 KINASE INHIBITORS IN MULTIPLE INDICATIONS Ambit to Receive a $40 Million Upfront Cash Payment; Up to $350 Million](https://www.pdfsearch.io/img/3dbde53f1d023d8a0c6d498f88985d49.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2009-12-17 23:42:07
|
---|
4![Microsoft Word - ASH 2012 Announcement Press Release - final Microsoft Word - ASH 2012 Announcement Press Release - final](https://www.pdfsearch.io/img/cc09757bae0a9d98deae3dc4315d817e.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2012-11-06 04:03:33
|
---|
5![Microsoft Word - ASH 2012 Announcement Press Release (final) Microsoft Word - ASH 2012 Announcement Press Release (final)](https://www.pdfsearch.io/img/64dc12ef5c0e11557f36265633ca12ed.jpg) | Add to Reading ListSource URL: www.astellas.comLanguage: English - Date: 2012-12-10 18:40:36
|
---|
6![AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA Potential to Support U.S. Regulatory Filing AMBIT BIOSCIENCES INITIATES FIRST PHASE 2 CLINICAL TRIAL OF AC220 IN ACUTE MYELOID LEUKEMIA Potential to Support U.S. Regulatory Filing](https://www.pdfsearch.io/img/402281a5e9338306996185be3fd10f11.jpg) | Add to Reading ListSource URL: www.forwardventures.comLanguage: English - Date: 2011-08-15 11:58:25
|
---|
7![Microsoft Word[removed]Partnership with Ambit.doc Microsoft Word[removed]Partnership with Ambit.doc](https://www.pdfsearch.io/img/80043791e6c796767f66a13415afd90d.jpg) | Add to Reading ListSource URL: www.forwardventures.comLanguage: English - Date: 2011-08-15 11:58:25
|
---|
8![Microsoft Word - ASH2009 Phase I study results - FINAL.doc Microsoft Word - ASH2009 Phase I study results - FINAL.doc](https://www.pdfsearch.io/img/37fea77ca37f57734a5b107807552fb5.jpg) | Add to Reading ListSource URL: www.forwardventures.comLanguage: English - Date: 2011-08-15 11:58:25
|
---|
9![CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1 CRENOLANIB, A NOVEL TYPE I, MUTANT-SPECIFIC INHIBITOR OF CLASS III RECEPTOR TYROSINE KINASES, PREFERENTIALLY BINDS TO PHOSPHORYLATED KINASES 1](https://www.pdfsearch.io/img/965e3e228a0b27196e47882e97a8efaf.jpg) | Add to Reading ListSource URL: www.gistsupport.orgLanguage: English - Date: 2013-01-20 11:10:44
|
---|